Top Abstract Purchase Related
Home
>
Node
>
Subnode

Managing acquired resistance in EGFR-mutated non-small cell lung cancer

Forde, P.M.; Ettinger, D.S.

Clinical Advances in Hematology and Oncology H&o 13(8): 528-532

2015

ISSN/ISBN: 1543-0790
PMID: 26351816
Document Number: 683779
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) deliver high response rates with relatively modest toxicity in patients with advanced EGFR-mutated non-small cell lung cancer. Despite this, nearly all tumors eventually develop resistance to first-line therapy. At present, the only standard treatment option for patients with acquired resistance is cytotoxic chemotherapy. In this article, we review the latest research into methods of targeting acquired resistance to EGFR TKI therapy, including third-generation EGFR TKIs that target the T790M resistance mutation and other novel agents in development.

Document emailed within 1 workday
Secure & encrypted payments

Li, J.; Hong, Q.; Zhang, X.; Hu, J.; Bai, C. 2014: Therapeutic efficacy and safety of chemotherapy subsequent EGFR-TKi in advanced non-small cell lung cancer patients with EGFR-TKi acquired resistance Zhonghua Yi Xue Za Zhi 94(30): 2342-2345
Shepherd, F.A. 2016: Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients Clinical Advances in Hematology and Oncology: H&o 14(1): 41-43
Jin, B.; Zhang, Y.; Zhang, X.; Li, R.; Lou, Y.; Niu, Y.; Huang, A.; Han, B. 2014: Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKi in advanced non-small cell lung cancer harboring EGFR mutations Zhonghua Yi Xue Za Zhi 94(30): 2327-2331
Levy, B.P.; Rao, P.; Becker, D.J.; Becker, K. 2016: Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors Oncology 30(7): 601-612
Dong, Q.-g.; Han, B.-h.; Huang, J.-s.; Yang, L.-m.; Huang, J.; Zhao, C.-y.; Lu, L.-q. 2006: Analysis of EGFR mutations in 176 cases of non-small cell lung cancer Zhonghua Zhong Liu Za Zhi 28(9): 686-690
Urata, Y.; Satouchi, M. 2015: I. what is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer? Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(8): 931-934
Zhang, J.Q.; Xu, F.; Xu, X.L.; Zhou, H.C. 2017: Erlotinib in the treatment of small cell lung cancer with EGFR mutation: a case report Zhonghua Zhong Liu Za Zhi 39(9): 717-719
Dahse, R.; Berndt, A.; Kosmehl, H. 2008: PCR-based testing for therapy-related EGFR mutations in patients with non-small cell lung cancer Anticancer Research 28(4b): 2265-2270
Yang, B.; Zheng, D.; Zeng, Υa.; Qin, A.; Gao, J.; Yu, G. 2018: Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(4): 1077-1081
Li, Z.; Zhang, L-jun.; Wang, W-ping.; Guo, K.; Shao, J-yong.; Rong, T-hua. 2011: Correlation between EGFR gene mutation and high copy number and their association with the clinicopathological features in Chinese patients with non-small cell lung cancer Zhonghua Zhong Liu Za Zhi 33(9): 666-670
Saxena, A.; Nagasaka, M.; Li, Z.; Becker, D.J.; Levy, B.P. 2014: Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer Oncology 28(6): 526; 528 530, 534
Shi, Y. 2015: The Guideline for Diagnosis and Treatment of Chinese Patients with sensitizing EGFR Mutation or ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2015 Version) Zhonghua Zhong Liu Za Zhi 37(10): 796-799
Xu, C.-a.; Su, H.; Liu, J.-l.; Li, L.; Zou, H.-w. 2011: Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor Zhonghua Zhong Liu Za Zhi 33(6): 436-441
Takeda, K. 2009: Overcoming resistance to EGFR-TKi in lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(4): 552-556
Watzka, S.B.; Posch, F.; Hochmair, M.; Setinek, U.; Köstler, W.J.; Müller, M.R. 2011: Resistance to EGFR targeting therapies in lung cancer Minerva Chirurgica 66(5): 483-494
Neill, H.B.; Miller, A.A.; Clamon, G.H.; Perry, M.C.; Crawford, J.; Green, M.R. 1997: A phase Ii study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer Seminars in Oncology 24(4 Suppl 12: S12
Gombos, Z.; Danihel, L.; Puttaswamy, K.; Brose, M. 2010: A comparative study of EGFR mutation screening methods in non-small cell carcinoma of lung Bratislavske Lekarske Listy 111(7): 365-368
Galimberti, S.; Marchetti, A.; Buttitta, F.; Carnicelli, V.; Pellegrini, S.; Bevilacqua, G.; Petrini, M. 1998: Multidrug resistance related genes and p53 expression in human non small cell lung cancer Anticancer Research 18(4c): 2973-2976
Kumar, A.; Ramanathan, K. 2015: Analyzing resistance pattern of non-small cell lung cancer to crizotinib using molecular dynamic approaches Indian Journal of Biochemistry and Biophysics 52(1): 23-28
Zhang, R.; Li, Y.; Chen, Y.; Liu, X.; Wang, Z.; Sun, H.; Zheng, Y.; Ding, Z.; Lan, L.; Li, M.; Qin, J.; Chen, X. 2015: Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer Zhonghua Yi Xue Za Zhi 95(47): 3839-3842